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1  | BACKGROUND
The dystroglycan (DG) adhesion complex takes center stage in a num‐
ber of physiological and pathological contexts, playing a particularly 
important role in skeletal muscle.1 It is composed of two subunits, the 
extracellular and highly glycosylated α‐DG and the transmembrane 
β‐DG, which act as a molecular link forming an axis between the ex‐
tracellular matrix and the internal cytoskeleton (Figure 1).2,3 DG is 
the major non‐integrin cell adhesion complex and its role is to offer 
stability to a number of tissues: skeletal and smooth muscle, brain 
and peripheral nervous system, at the neuromuscular junction, at the 
interface between endothelial cells and the surrounding astrocytes 
end‐feet at the blood–brain barrier, in the kidney glomeruli base‐
ment membrane and in lungs at the epithelia‐connective border.4‐6 
In addition, DG is fundamental during mouse embryogenesis, which 
is blocked as early as day 6.5 in dag1 knockout experiments.7
Interestingly, in invertebrates the full absence of DG, as in the C 
elegans knockout or a significant reduction in its expression levels, 
as in Drosophila do not give rise to muscle‐related phenotypes.8,9 
On the other hand, a family of patients in which some members dis‐
played a homozygous frameshift mutation resulting in a complete 
lack of the DG complex, shows a condition leading to the severe 
Walker‐Warburg syndrome and brain‐associated problems (ie, tec‐
tocerebellar dysraphia), and to early lethality.10,11
A few diverse α‐DG binding partners have been identified so far 
in different tissues, such as laminins, perlecan, agrin, neurexins, pi‐
kachurin and slits.12 All these proteins share laminin‐globular (LG) 
domains employed in binding extracellular α‐DG, and they require 
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Abstract
Dystroglycan is a major non‐integrin adhesion complex that connects the cytoskele‐
ton to the surrounding basement membranes, thus providing stability to skeletal 
muscle. In Vertebrates, hypoglycosylation of α‐dystroglycan has been strongly linked 
to muscular dystrophy phenotypes, some of which also show variable degrees of 
cognitive impairments, collectively termed dystroglycanopathies. Only a small num‐
ber of mutations in the dystroglycan gene, leading to the so called primary dystrogly‐
canopathies, has been described so far, as opposed to the ever‐growing number of 
identified secondary or tertiary dystroglycanopathies (caused by genetic abnormali‐
ties in glycosyltransferases or in enzymes involved in the synthesis of the carbohy‐
drate	building	blocks).	The	few	mutations	found	within	the	autonomous	N‐terminal	
domain of α‐dystroglycan seem to destabilise it to different degrees, without influ‐
encing the overall folding and targeting of the dystroglycan complex. On the contrary 
other mutations, some located at the α/β interface of the dystroglycan complex, 
seem to be able to interfere with its maturation, thus compromising its stability and 
eventually leading to the intracellular engulfment and/or partial or even total degra‐
dation of the dystroglycan uncleaved precursor.
K E Y W O R D S
dystroglycan, dystroglycanopathies, missense mutations, molecular analysis, protein domains
2  |     BRANCACCIO
calcium to establish additional coordination contacts with the sugar 
moieties protruding from it.13 The DG affinity towards these ligands 
is	generally	high	 (Kds within the nanomolar range) and can be also 
influenced by the heterogeneous glycosylation of α‐DG.12
The α‐DG/laminin interaction is considered crucial for the sta‐
bility of basement membranes. Intracellularly, the transmembrane 
β‐DG subunit does establish contacts with dystrophin and the cy‐
toskeleton (see Figure 1). Due to these pivotal structural functions, 
DG and its associated proteins, as well as the enzymes responsible 
for its post‐translational maturation, are heavily involved in several 
forms of muscular dystrophy.14,15 As a matter of fact sugar moieties, 
including a crucial phosphorylated O‐linked mannose,17,18 that pro‐
trude from the central mucin‐like domain of α‐DG have been re‐
cently found to be important for efficient binding to matrix partners, 
and hypoglycosylation of α‐DG is thought to represent a distinctive 
molecular trait leading to several human pathologies, in particular to 
an increasing number of neuromuscular disorders.
2  | THE E XPANDING GAL A X Y OF 
DYSTROGLYC ANOPATHIES
Dystroglycanopathies are genetic diseases often arising from the 
hypoglycosylation of α‐DG and, depending on the affected genes 
they originate from, they are classified in the following main groups: 
(a) primary dystroglycanopathies, which occur when mutations of 
the DAG1 gene alter the state of the DG core protein with poten‐
tial repercussions on the glycosylation state of α‐DG; (b) secondary 
dystroglycanopathies, which depend on genetic abnormalities of 
POMGnT1, POMT1 or LARGE1 among others. These result in mal‐
functioning of the corresponding enzymes involved in the decora‐
tion with sugars of the DG core protein in the endoplasmic reticulum 
(ER) and Golgi, often affecting severely the glycosylation of α‐DG; (c) 
tertiary dystroglycanopathies, possibly involving genes (such as ISPD 
or GMPPB) and their corresponding enzymes responsible for the 
fabrication of the carbohydrate building blocks in the cytosol, thus 
indirectly modifying α‐DG glycosylation.19 The spectrum of second‐
ary/tertiary dystroglycanopathies is likely to be even wider, since 
a link has been recently found between a dystrophic phenotype 
F I G U R E  1  Schematic	representation	of	the	dystrophin‐
glycoprotein complex (DGC) in skeletal muscle. The two 
dystroglycan subunits interact non‐covalently to form a bridge 
between the extracellular matrix and the actin cytoskeleton. α‐DG 
and β‐DG are non‐covalently connected and they also interact 
with numerous other proteins. The cytosolic domain of β‐DG is 
anchored to actin through the interaction with dystrophin and 
β‐DG also constitutes a scaffold for proteins involved in signal 
transduction	such	as	Gbr2	and	ERK.	α‐DG is a so‐called peripheral 
membrane protein that interacts with the ectodomain of β‐DG 
on the extracellular side of the plasma membrane. α‐DG acts as a 
receptor for extracellular matrix proteins such as laminins (reported 
in the scheme), perlecan, neurexins and agrin among others
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TA B L E  1  Mutations	inducing	primary	dystroglycanopathies	identified	in	vertebrates	(human	patients	and	zebrafish,	Danio rerio) so far
Mutation DG Subunit/Domain Phenotype Genotype Reference
L86Fa N‐term/α‐DG (IG1) Arrhythmogenic cardiomyopathy? Heter. 21
V74I,D111N N‐term/α‐DG (IG1) Asymptomatic	hyperCKemia,	mild	MD Comp. heter. 22
T192M N‐term/α‐DG	(S6) Limb‐girdle	MD	(LGMD2P),	cognitive	impair. Homoz. 23
Stop	codon	at	pos.266	
(c.743delC ‐ single bp deletion)
N‐term/α‐DG	(S6) Severe	WW‐phenotype,	death	upon	birth Homoz. 10
Stop	codon	at	pos.398	(D rerio 
R398>stop, would correspond 
to R389 in humans)
mucin/α‐DG Muscular	Dystrophy Homoz. 24
V567D (D rerio, would be I593 in 
humans)
C‐term/α‐DG (IG2) Muscle	degeneration,	impaired	mobility Homoz. 25
C669F N‐term/β‐DG 
(ectodomain)
Muscle‐Eye‐Brain	disease,	multicystic	leukodystrophy Homoz. 26
R776C β‐DG (cytodomain) Late‐onset limb‐girdle muscular dystrophy Homoz. 27
aIt might represent a rare variant rather than a mutation. It is not clear if there is a contribution to the observed pathology coming from DG in this case. 
Moreover,	no	data	have	been	collected	to	clarify	whether	α‐DG is abnormally glycosylated in this family. 
     |  3BRANCACCIO
depending on α‐DG hypoglycosylation and mutations in protein 
complexes responsible for localizing proteins to the Golgi compart‐
ment.20 As opposed to the constantly growing number of secondary 
and tertiary dystroglycanopathies so far identified, only a few cases 
of primary dystroglycanopathies have been found in human patients 
as well as in zebrafish. In Table 1 is reported a re‐collection of the rel‐
evant pathologic and genetic details behind the mutations identified 
to date. Different phenotypes have been observed, ranging from 
mild	muscular	dystrophy	with	asymptomatic	hyperCKemia	to	more	
severe	limb‐girdle	muscular	dystrophy	or	Muscle‐Eye‐Brain	disease.
3  | HETEROGENEIT Y OF PRIMARY 
DYSTROGLYC ANOPATHIES
Contrary to the increasing number of described secondary and ter‐
tiary dystroglycanopathies, primary dystroglycanopathies are com‐
paratively less studied due to the small number of cases identified 
so far. DAG1 mutations are rare, recessive mutations that are found 
in	consanguineous	families.	No	relevant	effects	of	the	DAG1 muta‐
tions	have	been	reported	so	far	on	their	corresponding	mRNA	levels.	
The few mutations so far identified can be visualized in the context 
of the DG complex domain structure (Figure 2), as they have been 
found	either	within	the	N‐terminal	region	of	α‐DG that represents 
an autonomous folding unit, or within regions located further down‐
stream and involved in the formation and stability of the α/β DG 
complex.1,28
Primary	dystroglycanopathies	arising	from	mutations	at	 the	N‐
terminal region of α‐DG can present with a series of symptoms (rang‐
ing from severe to milder cases), in line with the variability of the 
phenotypes observed in secondary dystroglycanopathies. However, 
it is interesting to notice that in the cases analysed the DG complex 
does not suffer a major disruption, and although different degrees of 
hypoglycosylation can be observed (influencing the affinity towards 
laminin), the two DG subunits are produced and trafficked to the 
membrane.	Thus,	missense	mutations	within	the	N‐terminal	region	
of α‐DG do not generally affect the overall folding, maturation and 
targeting of the DG complex to the plasma membrane. They are 
likely to act in a subtler fashion, ie by locally altering the structure of 
the	first	Ig‐like	domain	or	of	the	S6	domain,	or	alternatively	the	over‐
all	flexibility	of	the	whole	N‐terminal	domain.	These	effects	would	
influence	 the	 “chaperoning	 role”	 that	 the	N‐terminus	 of	α‐DG ex‐
erts on the glycosyltransferase LARGE.29 Due to the observed high 
flexibility within the two subdomains of α‐DG	N‐terminal	region,	it	
can be speculated that some of these mutations might also affect 
the interactions between DG and other enzymes important for the 
post‐translational glycosylation of DG in the Golgi (decoration pro‐
cess) still without inhibiting the maturation of the α/β complex into 
its two subunits.30,31
On the other hand, both in human patients and zebrafish, phe‐
notypes can also arise when mutations are found at the interface 
formed by α‐DG and β‐DG that is ultimately responsible for the 
non‐covalent interaction between the two subunits.33 In one case 
a missense mutation within the second Ig‐like domain of α‐DG, 
V567D, was shown to induce the patchy‐tail phenotype in zebras‐
fish typically caused by the total absence of DG.25 A complete lack 
of DG has also been observed in another zebrafish mutant in which 
a nonsense mutation was found within the mucin‐like region of α‐
DG.24 It is worth to note that the case identified by Riemersma 
and	colleagues	(with	a	nonsense	stop	codon	at	the	level	of	the	S6	
domain of α‐DG resulting in the full depletion of the whole DG 
complex) might represent the nearest human counterpart to these 
mutations.10
Our group has a long‐standing tradition of molecular studies on 
DG, for example by modelling and molecular dynamics, we have 
shown that the V567D zebrafish mutation, as well as its murine topo‐
logical counterpart I591D, is likely to introduce a degree of instability/
collapse within the α‐DG IG‐like β‐sandwich structure, leading to the 
F I G U R E  2   Domain structure of the dystroglycan complex with missense/nonsense mutations into their domain/structural context. 
Red	dots	at	the	top	of	the	domain	structure	indicate	the	missense	mutations	so	far	identified.	Namely,	from	left	to	right	(N‐terminus	to	C‐
terminus):	V74I,	L86F,	D111N,	T192M,	V567D	(zebrafish),	C669F	and	R776C.	A	“stop”	label	marks	the	mutations	introducing	a	frameshift	
reading	error	and	a	subsequent	nonsense	codon	within	the	S6	domain	(human)	and	the	presence	of	a	nonsense	codon	(in	the	mucin‐like	
region	of	zebrafish).	SP:	signal	peptide,	IG1	&	IG2:	immunoglobulin‐like	domains,	S6:	domain	similar	to	ribosomal	protein	S6,	black	arrow:	
furin cleavage site at Arg 312, mucin‐like: highly glycosylated and elongated central domain of α‐DG,	MAT:	the	α/β maturation interface that 
includes	the	Gly‐Ser	653‐654	cleavage	site	(red	arrow),	βBS:	β‐dystroglycan	binding	site	on	the	IG2	domain,	NU:	natively	unfolded	–	it	refers	
to the ectodomain of β‐DG,	TM:	transmembrane	stretch,	Cyto:	cytodomain	of	β‐DG	which	includes	its	dystrophin‐binding	site	(DBS)
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exposure of some hydrophobic internal residues.34 In another case, 
the C669F mutation affecting the ectodomain of β‐DG was shown 
to	cause	a	severe	Muscle‐Eye‐Brain	disease	with	a	relevant	pheno‐
type involving the white matter in the brain displaying as multicys‐
tic leukodystrophy.26 Recently, we have shown that such conditions 
could depend on the intracellular engulfment within the ER of the DG 
unprocessed precursor, eventually leading to its likely ubiquitination 
and consequent degradation by the proteasome.35 It has yet to be 
assessed whether the pathologic consequences of this mutation de‐
pend on (a) the absence of DG properly targeted at the sarcolemma/
plasma membrane, or on (b) the accumulation of intracellular DG due 
to its engulfment into the ER The evidence that no dominant negative 
effects have been observed in heterozygous carriers of the mutation 
seems to make the latter hypothesis less likely.26
It is perhaps not surprising that genetic abnormalities within the 
area responsible for the maturation of the DG complex, in which po‐
sitions	653‐654	(Gly‐Ser	in	human)	are	highly	conserved	and	repre‐
sent the site for cleavage of the precursor into α‐ and β‐DG, result in 
very serious pathologies. Apparently in fact only a very small frac‐
tion of such an anomalous DG uncleaved precursor, whose partial 
degree of glycosylation is probably insufficient for efficient laminin 
binding, can make it to the membrane, where the correctly cleaved 
α/β–complex is not detected.35
The α/β interface of DG (ie C‐terminal domain of α‐DG and ect‐
odomain of β‐DG),	harbouring	a	SEA	module,	was	shown	to	have	an	
important role in post‐translational processing, trafficking and tar‐
geting of the entire complex.36 From an evolutionary standpoint, the 
α/β interface seems to be the most ancestral and the true Achille's 
heel of the complex, as revealed by experimental evidence of the 
whole α/β interface to constitute the target of some specific matrix 
metalloproteinases degrading action.1,37 This may have important 
pathological consequences in tissue remodelling upon wound‐heal‐
ing and chronic inflammation, leading to muscular dystrophy but also 
to cancer invasion.
Very recently a first mutation within the cytodomain of β‐DG, 
namely R776C, has been identified, causing a late‐onset form of 
limb‐girdle muscular dystrophy (see Table 1).27 This arginine is the 
first residue of the cytosolic domain of β‐DG, that is, it is part of its 
nuclear localization peptide and might represent a putative dock‐
ing	 site	 for	MAPK.27 Interestingly, the effect of R776C could also 
depend on it being a mutation in the basic sequence that governs 
membrane orientation of transmembrane proteins.38
4  | CONCLUSIONS
New	mutations	in	DAG1 are likely to be identified in the future, and it 
will be interesting to assess their effect in view of the ongoing domain 
structural assessment and the possible collection of further additional 
structural information. A system and rationale for the classification of 
a larger amount of information (ie, mutations) based on the molecu‐
lar structure of DG is likely to become a priority in the future, once a 
statistically significant amount of mutations has been characterised.
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